Company intelligence / Profile preview

Stratipath

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

Stratipath's AI-powered breast cancer risk profiling solution (Stratipath Breast) is CE-IVD marked, validated in independent clinical studies, and integrated with major digital pathology platforms. It offers rapid prognostic risk stratification as an alternative to costly and time-consuming molecular assays, improving decision support in breast cancer diagnosis and treatment.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapySoftware-as-a-Service
Industry: Pathology

Partnerships

Roche (distribution and technical integration with navify Digital Pathology)Sectra (integration with digital pathology PACS system)

Beyond the preview

Go deeper on Stratipath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stratipath.

Explore the full profile